Aeterna Zentaris (AEZS) Posts Q3 Loss of 19c, Beats by 2c
More News related to AEZS
- Emerging Stock Report Initiates Independent Research Coverage on AEterna Zentaris Inc.
- Morning Movers 11/24: IWA, SEED, FEED, AEZS Higher; WH, ORS, ABIO, GRO, LONG Lower
- AEterna Zentaris (AEZS) Announces Phase 2 Results of AEZS-108 Endometrial Cancer Treatment
- AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
Aeterna Zentaris Inc. (NASDAQ: AEZS) reports Q3 loss of $0.19, 2 cents better than the analyst estimate of ($0.21). Revenue for the quarter was $8.57 million, which compares to the estimate of $8.04 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
